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CD44 phosphorylation regulates melanoma cell and fibroblast
migration on, but not attachment to, a hyaluronan substratum
David Peck and Clare M. Isacke
Background: CD44 is a transmembrane receptor for the extracellular matrix
glycosaminoglycan, hyaluronan. This receptor–ligand interaction plays an
essential role in tumour progression, in embryonic tissue morphogenesis and in
leukocyte migration during inflammation. It is well documented that the interaction
between CD44 and hyaluronan is strictly regulated, but little is known about the
relationship between hyaluronan-dependent cell adhesion and cell migration.
Results: In these studies we have used a CD44-negative human melanoma cell
line and a murine fibroblast line which expresses low levels of endogenous
CD44. Both cell lines were transfected with plasmids encoding wild-type human
CD44 or CD44 phosphorylation mutants, in which the target serines had been
mutated to small neutral amino acids or large acidic residues. We show that
expression of wild-type CD44 enhances the ability of both cell lines to bind to,
and migrate on, a hyaluronan-coated substratum. In contrast, the two CD44
phosphorylation mutants were as efficient as wild-type CD44 in mediating cell
adhesion but were unable to support hyaluronan-dependent migration.
Conclusions: These studies demonstrate a control mechanism specific for
CD44-mediated cell motility and have implications for the regulation of
metastatic progression by cell-adhesion receptors.
Background
The process by which malignant cells disseminate from a
primary tumour to form secondary (metastatic) tumours
involves a complex series of changes in cell adhesion and
motility. Key steps in this process are: a reduction in adhe-
sion to the neighbouring tumour cells, balanced by
increased adhesion to the extracellular matrix; degradation
of this matrix; migration through the stroma; entry and exit
from the circulation whilst evading immune surveillance;
and proliferation in a secondary site. In all of these steps,
plasma membrane adhesion/recognition receptors play a
crucial role. In recent years, particular interest has focussed
on CD44 and its principle ligand, the extracellular matrix
glycosaminoglycan, hyaluronan. It has been demonstrated
that the interaction between CD44 and hyaluronan can be
an essential component of tumour growth and metastasis,
as well as of a variety of normal physiological events [1]. 
CD44 is an integral membrane glycoprotein comprised of
a 37 kDa protein core that is extensively modified by N-
and O-linked glycosylation and the variable addition of
chondroitin and heparin sulphate side chains. Different
forms of CD44 can also be produced by the insertion of
combinations of ten alternatively spliced exons into the
extracellular domain [2]. It is known that the ability of
CD44 to interact with its ligand is subject to a number of
regulatory mechanisms, including conformational changes
in the extracellular domain and/or clustering of the receptor
[3], insertion of alternatively spliced exons [4–6] and glyco-
sylation [7,8]. In addition, there is an ‘inside-out’ signalling
component, in that removal of the highly conserved 70-
amino-acid cytoplasmic domain can abrogate binding to
hyaluronan [9–12]. Despite these advances in understand-
ing the control of hyaluronan binding, little is known
about the mechanisms that control hyaluronan-mediated
cell migration other than that the expression of a
hyaluronan-binding form of CD44 is required [5].
CD44 is subject to phosphorylation by a serine/threonine
protein kinase [13,14], and mutational analysis has shown
that the serine residues at positions 323 (Ser323) and/or
325 (Ser325) are the target residues in human [15] and
murine [11] CD44. A range of phosphorylation mutants in
which these target serines have been changed in various
combinations to aspartic acid, glutamic acid, glycine or
alanine have been generated. When expressed in CD44-
negative AKR1 T-lymphoma cells, the human wild-type
CD44 and all of the CD44 phosphorylation mutants are
equally efficient in binding soluble FITC-conjugated
hyaluronan, and in mediating cell attachment to a hyaluro-
nan substrate; however, removal of the cytoplasmic
domain abrogates the ability of CD44 to bind to hyaluro-
nan [12]. Although it was found that phosphorylation did
not play a role in mediating CD44–hyaluronan interac-
tions when CD44 was expressed in AKR1 cells, it was sug-
gested in these studies that, in adherent cell lines,
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phosphorylation might regulate CD44-dependent migra-
tion on a hyaluronan substratum. To investigate this possi-
bility we have chosen to study two cell lines, RPM-MC
cells and L cells. The human RPM-MC cell line was
derived from a recurrent cutaneous melanoma and has
undetectable levels of CD44 expression [16]. In contrast,
murine L-cell fibroblasts endogenously express the
haematopoietic CD44H isoform. Here we present evi-
dence which suggests that CD44 phosphorylation is criti-
cal for migration, but not for adhesion,  in both cell types.
Results
The characteristics of binding to soluble hyaluronan by
CD44-expressing AKR1 cells has been carefully docu-
mented by Perschl et al. [17]. These authors have shown
that in clonal transfectants, a threshold of CD44 expres-
sion is required before hyaluronan binding is detected,
and that above this threshold there is considerable vari-
ability in the distribution of hyaluronan binding relative to
CD44 expression. Using a similar analysis we have shown
that clonal RPM-MC cell lines transfected with a plasmid
expressing human CD44 exhibit equivalent binding char-
acteristics (Fig. 1). Moreover, we found no reproducible
differences in hyaluronan binding between wild-type
CD44 and two CD44 phosphorylation mutants, in which
the target serine residues, Ser323 and Ser325, had been
changed to Gly323 and Ala325 (GA CD44) [15] or to
Glu323 and Glu325 (EE CD44) [12].
Given these results it was important to show that the
ability of the phosphorylation mutants to bind to soluble
Figure 1
CD44 phosphorylation mutants mediate efficient soluble hyaluronan
binding. The transfected RPM-MC clonal cell lines Vector1, WT1, GA1
and EE1 (see Table 1) were labelled with FITC–hyaluronan (FITC–HA)
and CD44 was labelled with monoclonal antibody E1/2 and detected
with phycoerythrin (anti-CD44–PE) as previously described [12].
Samples were then analyzed by two-colour flow cytometry. The data
are represented as the median FITC–HA fluorescence calculated over
50 channel intervals of phycoerythrin fluorescence. The results
obtained from the CD44-negative Vector1 clone are not shown, as
more than 95 % of the cells showed anti-CD44–PE and FITC–HA
labelling of less than 100.
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Table 1
Comparison of independent clonal RPM-MC and L-cell lines
expressing CD44 and CD44 phosphorylation mutants.
Cell line Human CD44 Adhesion (%) Migration (mm)
expression
RPM-MC clones
Vector1 0 32 0.46
Vector2 0 30 0.42
WT1 68 97 0.90
WT2 64 91 0.84
WT3 61 82 0.83
GA1 80 96 0.47
GA2 64 83 0.43
GA3 13 46 0.42
EE1 70 90 0.41
EE2 64 84 0.42
EE3 55 80 0.45
L-cell clones
Vector1 0 38 0.22
Vector2 0 34 0.20
WT1 63 70 0.38
WT2 70 72 0.39
WT3 74 69 0.38
WT4 58 64 0.34
GA1 65 71 0.18
GA2 38 45 0.21
GA3 46 53 0.19
GA4 59 68 0.14
EE1 59 78 0.17
EE2 54 60 0.19
EE3 52 51 0.20
A number of independent clonal lines were isolated from each
transfection: Vector, cells transfected with the vector alone; WT, cells
transfected with plasmid encoding wild-type CD44; GA, cells
transfected with plasmid encoding the CD44 phosphorylation mutant
GA CD44; EE, cells transfected with plasmid encoding the CD44
phosphorylation mutant EE CD44. Human CD44 expression was
measured by enzyme-linked immunosorbent assay (ELISA) and values
given are in arbitrary units per 106 cells. In parallel assays, F1084
human diploid fibroblasts had a CD44 expression level of 61. In
separate assays using the murine CD44-specific monoclonal antibody
KM201, the level of endogenous CD44 expression on L-cell fibroblasts
was 42 % of that found on Swiss 3T3 fibroblasts. Adhesion to, and
migration on, a hyaluronan-coated substratum was assayed as
described in Materials and methods (see also Figs 2 and 4). For
adhesion, 100 % values relate to the number of cells seeded. For
migration, values given represent mm of wound closure over a 48 h
period. Each value represents the mean of at least three
determinations. In all subsequent figures data is shown for the Vector1,
WT1, GA1 and EE1 cell lines derived from RPM-MC cells and L cells.
hyaluronan reflected an ability to mediate cell adhesion to
a hyaluronan-coated substratum, as this is a more physio-
logically relevant assay. To this end, we tested a number
of independent RPM-MC transfectants in a plate-binding
assay; CD44 expression levels were assayed in parallel
(Table 1). In eight of the nine transfected cell lines, the
levels of human CD44 expression were 90–131 % of those
found on human F1084 fibroblasts, and all eight showed
enhanced adhesion to hyaluronan-coated plates. The
exception was the RPM-MC clone GA3, which expressed
very low levels of the mutant CD44 protein and bound to
hyaluronan at a level only marginally above background.
As shown in Figure 2a, the enhanced binding seen in the
representative RPM-MC transfectants (WT1, GA1 and
EE1; see Table 1) was significantly reduced by pre-incu-
bating the cells with the anti-human CD44 monoclonal
antibody E1/2. Of interest is the observation that parental
cells and cells transfected with vector alone (neither of
which expressed CD44) both adhered more strongly to
wells coated with hyaluronan than to BSA-coated control
wells, indicating that a hyaluronan receptor other than
CD44 is expressed by RPM-MC cells.
These studies were repeated using murine L-cell fibro-
blasts. These cells were chosen because it was important
to assess the behaviour of the mutant CD44 proteins in a
separate and distinct cell line, and in the context of an
endogenous CD44 background. The L-cell line
employed here expresses moderate levels of CD44 (38 %
of that detected on Swiss 3T3 fibroblasts), which results
exclusively from the expression of the haematopoietic
CD44H isoform (data not shown). As shown in Figure 2b,
parental L cells bound to hyaluronan-coated wells more
efficiently than to BSA-coated control wells. This binding
was mediated by endogenous CD44 because binding was
reduced to near background levels by pre-incubating the
L cells with the anti-mouse CD44 monoclonal antibody
KM201. When L cells were transfected with the plasmid
expressing human CD44 there was a significant increase
in their ability to bind to hyaluronan, and this increase
was abrogated if the cells were pre-incubated with the
anti-human CD44 antibody, E1/2. A comparison of the
binding characteristics of a number of independently iso-
lated transfectants demonstrated that, as with the RPM-
MC and AKR1 transfectants, the hyaluronan binding
mediated by the CD44 phosphorylation mutants was
indistinguishable from that mediated by wild-type CD44
(Table 1; Fig. 2b).
It has previously been shown that, when expressed in
RPM-MC cells, wild-type CD44 can promote migration
across a hyaluronan-coated substratum; however, neither a
non-hyaluronan-binding CD44 splice variant nor a CD44
mutant containing a truncated cytoplasmic domain have
this ability [5]. We were interested to determine whether
CD44 phosphorylation mutants that were competent to
bind hyaluronan were also able to mediate hyaluronan-
dependent cell migration. RPM-MC transfectants were
cultured to semi-confluence on hyaluronan or BSA-coated
plates, wounds (approximately 1.2 mm wide) were created
in the monolayer and wound closure was measured over a
48 hour period. In this assay, transfectants expressing
wild-type CD44 displayed a significantly increased migra-
tion rate on hyaluronan compared to cells transfected with
vector alone; this increased migration was CD44-specific
because it was blocked by the E1/2 antibody. Strikingly,
cell lines expressing equivalent levels of GA CD44 or
EE CD44 only migrated at background levels and this
migration was unaffected by the presence of the E1/2 anti-
body (Figs 3 and 4a). Interestingly, although the binding
of vector-transfected RPM-MC cells to hyaluronan-coated
plates was more efficient than the binding to BSA-coated
plates (Fig. 2a), there was no significant difference in cell
motility on the two surfaces.
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Figure 2
Cells transfected with plasmids encoding wild-
type CD44 or the phosphorylation mutants
exhibit enhanced binding to hyaluronan-coated
plates. Parental RPM-MC cells and the
transfected RPM-MC cell clones Vector1,
WT1, GA1 and EE1 (a), or parental L cells
and the transfected L-cell clones Vector1,
WT1, GA1 and EE1 (b), were detached from
tissue culture dishes and allowed to recover
for 60 min in Petri dishes in the presence or
absence of 400 mg ml–1 of the monoclonal
antibodies E1/2 or KM201. Cells were then
allowed to adhere to hyaluronan-coated wells
or bovine serum albumin (BSA)-coated control
wells for 30 min at 37 °C. After washing, the
number of adherent cells was measured by
adsorption of crystal violet. Values of 100 %
relate to the total number of cells seeded.
Each value represents the mean ± S.E.M of at
least three determinations.
Parental
RPM-MC clones
P
er
ce
nt
ag
e 
of
 c
el
ls
 b
ou
nd
100
75
50
25

0
BSA
HA
HA + E1/2
Vector1 WT1 GA1 EE1
(a)
L-cell clones
P
er
ce
nt
ag
e 
of
 c
el
ls
 b
ou
nd
(b)
Parental
100
75
50
25

0
HA
HA + E1/2
BSA
HA + KM201
Vector1 WT1 GA1 EE1
Research Paper  CD44 phosphorylation and cell motility Peck and Isacke    887
These results do not reflect abnormalities in the clonal cell
lines employed, as a number of independently isolated
transfectants gave essentially identical results (Table 1).
Furthermore, similar results were obtained with the L-cell
transfectants. We examined a number of independent
clonal cell lines and found that the expression of wild-type
CD44 led to an increase in hyaluronan-dependent L-cell
motility compared to parental cells or to cells transfected
with vector alone. This enhanced migration rate was not
seen in cells expressing the GA CD44 or EE CD44 phos-
phorylation mutants (Table 1; Fig. 4b). A noticeable
difference between L cells and RPM-MC cells was that L
cells transfected with vector alone exhibited an increased
migration rate on hyaluronan compared to BSA-coated
plates. This difference was a result of the fact that L cells
expressed endogenous CD44 because inclusion of the
KM201 antibody in the migration assay reduced hyaluro-
nan-dependent migration to levels seen on control plates.
Finally, these results demonstrating that CD44 phos-
phorylation mutants were unable to mediate hyaluronan-
dependent motility were confirmed using an independent
Figure 3
Migration of RPM-MC cells on hyaluronan is
increased by the expression of wild-type
CD44 but not by the CD44 phosphorylation
mutants. Wounds of approximately 0.6 mm
were created in RPM-MC Vector1, WT1, GA1
and EE1 clones cultured on hyaluronan-
coated plates. Wound sites were
photographed after 0, 24 and 48 h. Scale
bar = 300 mm.
Figure 4
CD44 phosphorylation mutants cannot
support hyaluronan-dependent motility in 
the wound-healing assay. (a) RPM-MC or (b)
L-cell Vector1, WT1, GA1 and EE1 clones
were cultured to semi-confluence on
hyaluronan-coated or BSA-coated control
plates for 16 hours. Wounds of approximately
1.2 mm (RPM-MC cells) or 0.6 mm (L cells)
were created and the wound closure
measured at 0 and 48 hours. Where
indicated, the E1/2 antibody was included
during the 48 hour assay. Each value
represents the mean ± S.E.M. of at least three
determinations.
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Transwell filter migration assay (Fig. 5). Expression of
wild-type CD44 in both cell lines resulted in a signifi-
cantly increased rate of migration compared to cells trans-
fected with vector alone; this increase was blocked if the
E1/2 antibody was included in the assay. As with the
wound-closure assay, the transmigration of vector-
transfected L cells on hyaluronan was reduced to back-
ground levels by the inclusion of the KM201 antibody in
the assay. This independent assay demonstrated that the
transmigration rates of both the GA CD44-expressing and
the EE CD44-expressing cells were the same as those of
cells transfected with vector alone, and that these back-
ground levels of migration were unaffected by the E1/2
antibody.
Discussion
Aberrant expression or overexpression of CD44 in cells
can result in the acquisition of a metastatic phenotype
[18–20]. Where it has been examined, the interaction
between CD44 and hyaluronan has been shown to be an
essential component of this process [21,22]. Given the
multistep nature of metastatic progression, it is important
to discriminate between mechanisms that regulate cell
adhesion and those that regulate cell migration.
It is clear that the ability of CD44 to bind hyaluronan is
strictly regulated and that this regulation can occur at a
number of levels. In addition to cells that constitutively
bind hyaluronan, it is known that some CD44-positive cells
cannot bind ligand unless induced to do so by multivalent
activating monoclonal antibodies. This activation can occur
at 4 °C and with paraformaldehyde-fixed cells, which sugg-
ests that these antibodies act by modulating cell-surface
distribution rather than by indirectly triggering intracellular
signalling pathways [3]. However, as these antibodies do
not stimulate hyaluronan binding in all CD44-positive non-
binding cells, other regulatory mechanisms, such as modu-
lation of glycosylation [7,8], must clearly play a part. In
addition, the ability of CD44 to interact with ligand may
critically depend on how the hyaluronan is presented. For
example, although removal of the cytoplasmic domain of
CD44 prevents it from binding to soluble FITC-conjugated
hyaluronan [9,11,12,17] it can still mediate cell adhesion to
hyaluronan-coated plates, albeit with a significantly lower
efficiency than wild-type CD44 [5,9]. One interpretation of
these data is that, when immobilized, hyaluronan can stabi-
lize CD44 clusters, thereby at least partly overcoming
receptor destabilization resulting from loss of the cytoplas-
mic domain. Such an interpretation is supported by data
demonstrating that the CD44 protein without the cytoplas-
mic domain can be induced to bind to soluble hyaluronan
either by incubation with an activating monoclonal anti-
body or by dimerization of the transmembrane domain [17].
The mechanism by which the cytoplasmic domain might
stabilize receptor clustering is unknown. Lokeshwar et al.
[10] have demonstrated a requirement for the proposed
ankyrin-binding domain (between Asn304 and Leu318) but
Perschl et al. [17] have created deletions within this domain
without impairing hyaluronan binding capacity. Whether
there is a specific inside-out signalling mechanism or a more
generalized sequence-independent role for the cytoplasmic
domain is not known. The data presented here indicate that
phosphorylation of Ser323 and/or Ser325 is not required. As
discussed in full elsewhere [12], there is a discrepancy
between these results and those of Puré et al. [11] who
reported that equivalent mouse phosphorylation mutants
exhibited a reduced hyaluronan-binding capacity. Of rele-
vance to this discrepancy are the studies of Lokeshwar et al.
[10] and Perschl et al. [17], who have demonstrated that pre-
mature truncation of the cytoplasmic domain of CD44 (at
Leu318 or Gly305, respectively), which removes the target
serine residues, does not impair ligand binding. By contrast,
our data would suggest that phosphorylation plays a crucial
role in outside-in signalling whereby an interaction with
extracellular ligand stimulates enhanced cell migration.
Figure 5
CD44 phosphorylation mutants cannot
support hyaluronan-dependent motility in a
Transwell-migration assay. (a) RPM-MC or (b)
L-cell Vector1, WT1, GA1 and EE1 clones
were seeded onto hyaluronan-coated or BSA-
coated control Transwell filters and the
number of cells which migrated into the lower
chamber over a 48 h period was determined.
Where indicated, the E1/2 or KM201
antibodies were present throughout the assay.
Each value represents the mean ± S.E.M. of
three determinations.
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In order for a cell to migrate there must be an interaction
between the matrix and a transmembrane receptor result-
ing in a cytoskeletal reorganization; these events must be
dynamic and involve the coordination of a number of
physical and/or signalling processes [23,24]. Changes in
the cytoskeletal distribution could result from a direct
interaction between CD44 and intracellular structural
components, in a manner similar to that by which the b1
integrin subunit binds to a-actinin and talin [25,26], which
link the integrin to the actin microfilaments. Consistent
with this idea are the membrane mobility studies of Jacob-
son et al. [27,28], where CD44 was shown to exhibit a
restricted mobility in fibroblasts, with a more rapid redis-
tribution at the leading edge than at the trailing edge of
motile cells. These data suggest that CD44 transiently
interacts with the cytoskeleton. Studies to identify CD44-
associated cytoskeletal components have been compli-
cated by the demonstration that although 30–80 % of the
CD44 remains associated with the detergent-insoluble
cytoskeletal fraction of migratory cells, this insolubility is
independent of the cytoplasmic domain and reflects a
function of the transmembrane domain, which probably
associates with Triton X-100-insoluble lipids [29–31].
Other approaches to identifying a direct association
between CD44 and the cytoskeleton have led to reports
that CD44 binds to ankyrin [10] and to members of the
ERM (ezrin, radixin and moesin) family [32]. The physio-
logical relevance of these interactions and the role of
CD44 phosphorylation in their regulation remains to be
determined.
In addition to (or instead of) a mechanical interaction, it is
possible that CD44 phosphorylation effects cytoskeletal
reorganization indirectly by the activation of a signalling
pathway. Precedents for such a mechanism arise from
studies with integrins [33]. Clustering of integrins acti-
vates the focal adhesion kinase resulting in autophospho-
rylation and the phosphorylation of a number of other
focal adhesion components, including paxillin and tensin.
These components are then primed to interact with key
components of intracellular signaling pathways that
contain phosphotyrosine-binding SH2 domains; these
interactions ultimately result in cytoskeletal reorganiza-
tion. More recently, the discovery of an integrin-associated
serine/threonine kinase that can phosphorylate the cyto-
plasmic domain of b1 integrin has suggested that there is
an additional signaling pathway [34]. Overexpression of
the kinase results in reduced cell adhesion and increased
anchorage-independent growth. In order to determine the
mechanisms by which CD44 phosphorylation regulates
cell migration, it will first be necessary to determine the
phosphorylation status of Ser323 and Ser325. We have
previously shown that mutation of either residue abolishes
CD44 phosphorylation [15], consequently it is not known
whether both serines are phosphorylated or whether one
serine acts as part of the kinase consensus site and is
therefore required for phosphorylation of the other. It will
then be necessary to identify the CD44 kinase and struc-
tural or signaling intracellular proteins that can discrimi-
nate between the phosphorylated and dephosphorylated
receptor.
Conclusions
As previously reported [5], we demonstrate in this paper
that expression of wild-type human CD44 in the CD44-
negative RPM-MC melanoma cells results in an enhanced
CD44-specific ability of these cells to bind to, and migrate
on, a hyaluronan-coated substratum. In order to determine
whether binding and migration are regulated separately, we
extended these studies to look at two different CD44 phos-
phorylation mutants and found that they retain the ability
to bind soluble and matrix-associated hyaluronan but
cannot support CD44-dependent migration on hyaluronan-
coated plates, or through hyaluronan-coated Transwell
filters. This is not a cell-type specific event as similar
results are obtained using transfected L-cell fibroblasts.
These studies demonstrate a distinct mechanism for the
control of CD44-dependent cell migration, which is consid-
ered to be a critical component in tumour progression and
metastatic spread. 
Materials and methods
Generation and characterization of transfected cell lines
The CD44 phosphorylation mutants, in which Ser323 and Ser325 of
the haematopoietic form of human CD44 were changed to Gly323 and
Ala325 (GA CD44) or to Glu323 and Glu325 (EE CD44), were
expressed from their respective cDNAs subcloned into the pSRa-neo
eukaryotic expression vector, as previously described [12,15]. RPM-MC
melanoma cells and L-cell fibroblasts cultured on 60 mm tissue culture
dishes were transfected with pSRa-neo vector alone, or vector express-
ing wild-type CD44 or CD44 phosphorylation mutants using the Cell
Phect Transfection kit (Pharmacia). After 16 h, cells were transferred to
150 mm dishes containing Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10 % fetal calf serum (FCS) and
0.5 mg ml–1 G418. After 10–14 days, G418-resistant single colonies
were isolated and analysed by immunofluorescence for human CD44
expression using the E1/2 monoclonal antibody [13]. Throughout these
studies independent transfected lines were continuously monitored for
human and murine CD44 expression by ELISA assay as follows: cells
were seeded at 8 × 103 cells per well in 96-well plates (Falcon) cultured
overnight, fixed with 3 % paraformaldehyde and incubated sequentially
with the E1/2 or KM201 monoclonal antibodies (25 mg ml–1) and HRP-
conjugated anti-mouse or anti-rat immunoglobulin (Vector Laboratories).
The reaction was visualized using the soluble peroxidase substrate, o-
phenylenediamine dihydrochloride (OPD; Sigma).
Hyaluronan binding
To measure adhesion to a hyaluronan substratum, 96-well tissue
culture plates were incubated for 32 h at 4 °C with 75 ml of 5 mg ml–1
Streptococcal hyaluronan (Calbiochem) per well. An equal volume of
2 % BSA was then added and the plates left for a further 16 h. Control
wells were incubated with a 1 % BSA solution only. All plates were
washed three times in DMEM containing 10 % FCS and used immedi-
ately. Cells were detached from subconfluent cultures by incubation for
5 min in a solution containing 0.25 % trypsin (Sigma) and 0.02 %
EDTA and allowed to recover in DMEM containing 10 % FCS for 1 h in
90 mm petri dishes (Sterilin). Cells (1.5 × 104) were added to triplicate
wells and allowed to adhere for 30 min at 37 °C. Non-adherent cells
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were removed by washing three times in DMEM containing 10 % FCS.
To determine the number of adherent cells, cells were fixed in 3 %
paraformaldehyde for 15 min, permeabilized in –20 °C methanol for
4 min, washed twice in PBS and 50 ml of 0.5 % crystal violet added
for 15 min followed by a final two washes in PBS. Dye was eluted
from cells with 50 ml of 10 % acetic acid and absorbance read at
595 nm. Where indicated, 400 mg ml–1 of the E1/2 antibody was
included in the 1 h recovery period. To measure binding of FITC-con-
jugated hyaluronan, cells were detached in 70 mM ice-cold EDTA
and flow cytometry and data analysis performed as previously
described [12,17].
Migration assays
For wound-healing assays, 24-well tissue culture plates (Falcon) were
hyaluronan-coated as described above. RPM-MC or L-cell lines were
seeded at 1.75 × 105 or 2.5 × 105 cells per well, respectively, and cul-
tured overnight in DMEM containing 10 % FCS. Wounds of approxi-
mately 0.6 mm (L cells) or 1.2 mm (RPM-MC cells) were gently scored
in the monolayers using a Gilson tip, the monolayers washed and the
wound width measured at four separate points using a graticule.
Closure was monitored at 24 and 48 h. Where indicated, 400 mg ml–1
of the E1/2 antibody was present during the migration assay and
replaced every 24 h. For Transwell migration assays, 24 mm polycar-
bonate Transwell filters (8 mm Costar) were coated with hyaluronan or
BSA as described above. Cells (1.5 × 104) were seeded onto the filter
and cultured for 48 h in DMEM containing 10 % FCS. After 48 h, the
number of cells that had migrated through the filter was determined.
Filters were fixed and stained as described above. Cells on the upper
face of the filter were then removed by scraping, and the dye in the
cells on the lower face (migrated cells) was eluted in 50 ml of 10 %
acetic acid and the absorbance read at 595 nm. Where indicated,
400 mg ml–1 of the E1/2 antibody was added at the time of seeding
and replaced every 24 h.
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